Skip to content

Nuvalent, Inc. NUVL Additional Paid-In Capital

Additional Paid-In Capital at other companies

Pfizer logo
PfizerPFE
$94.77B+1.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$3.46B+19.6%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$3.02B+87.0%
Exelixis logo
ExelixisEXEL
$2.15B-6.1%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$4.82B+19.8%
Incyte logo
IncyteINCY
$5.08B+10.8%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s additional paid-in capital?
Nuvalent, Inc. (NUVL) reported additional paid-in capital of $2.26B in Q1 2026.
How has Nuvalent, Inc.'s additional paid-in capital changed year-over-year?
Nuvalent, Inc.'s additional paid-in capital increased by 37.5% year-over-year, from $1.64B to $2.26B.
What is the long-term trend for Nuvalent, Inc.'s additional paid-in capital?
Over 5 years (2020 to 2025), Nuvalent, Inc.'s additional paid-in capital has grown at a 383.2% compound annual growth rate (CAGR), from $842K to $2.22B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.